vimarsana.com

Latest Breaking News On - University of copenhagen novo nordisk foundation center - Page 1 : vimarsana.com

Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal

Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.

vimarsana © 2020. All Rights Reserved.